Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

The need for contraception in patients taking prescription drugs: a review of FDA warning labels, duration of effects, and mechanisms of action.

Zhang Z, Xu L, Zhang Z, Ding H, Rayburn ER, Li H.

Expert Opin Drug Saf. 2018 Nov 3:1-13. doi: 10.1080/14740338.2018.1544617. [Epub ahead of print]

PMID:
30394114
2.

FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction.

Rayburn ER, Gao L, Ding J, Ding H, Shao J, Li H.

J Assist Reprod Genet. 2018 Feb;35(2):191-212. doi: 10.1007/s10815-017-1062-8. Epub 2017 Oct 24. Review.

PMID:
29063992
3.

FDA-approved medications that impair human spermatogenesis.

Ding J, Shang X, Zhang Z, Jing H, Shao J, Fei Q, Rayburn ER, Li H.

Oncotarget. 2017 Feb 7;8(6):10714-10725. doi: 10.18632/oncotarget.12956. Review.

4.

FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels.

Yao H, Rayburn ER, Shi Q, Gao L, Hu W, Li H.

Crit Rev Clin Lab Sci. 2017 Jan;54(1):1-17. doi: 10.1080/10408363.2016.1191425. Epub 2016 Jun 27. Review.

PMID:
27193822
5.

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R.

PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.

6.

Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.

Li H, Ezell SJ, Zhang X, Wang W, Xu H, Rayburn ER, Zhang X, Gurpinar E, Yang X, Sommers CI, Velu SE, Zhang R.

Biomed Chromatogr. 2011 May;25(5):628-634. doi: 10.1002/bmc.1498. Epub 2010 Sep 15.

7.

Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Ezell SJ, Li H, Xu H, Zhang X, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W, Zhang R.

Mar Drugs. 2010 Jul 13;8(7):2129-41. doi: 10.3390/md8072129.

8.

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Wang W, Rayburn ER, Velu SE, Chen D, Nadkarni DH, Murugesan S, Chen D, Zhang R.

Breast Cancer Res Treat. 2010 Sep;123(2):321-31. doi: 10.1007/s10549-009-0638-0. Epub 2009 Nov 21.

9.

Recent advances in validating MDM2 as a cancer target.

Rayburn ER, Ezell SJ, Zhang R.

Anticancer Agents Med Chem. 2009 Oct;9(8):882-903. Review.

PMID:
19538162
10.

In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.

Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R.

Clin Cancer Res. 2009 May 15;15(10):3511-8. doi: 10.1158/1078-0432.CCR-08-2689.

11.

Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.

Nadkarni DH, Wang F, Wang W, Rayburn ER, Ezell SJ, Murugesan S, Velu SE, Zhang R.

Med Chem. 2009 May;5(3):227-36.

PMID:
19442212
12.

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.

Wang F, Ezell SJ, Zhang Y, Wang W, Rayburn ER, Nadkarni DH, Murugesan S, Velu SE, Zhang R.

Invest New Drugs. 2010 Jun;28(3):234-41. doi: 10.1007/s10637-009-9232-x. Epub 2009 Mar 10.

PMID:
19274441
13.

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.

Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R.

Cancer Lett. 2009 Jun 18;278(2):241-248. doi: 10.1016/j.canlet.2009.01.005. Epub 2009 Feb 8.

14.

Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

Wang W, Rayburn ER, Hang J, Zhao Y, Wang H, Zhang R.

Lung Cancer. 2009 Sep;65(3):306-11. doi: 10.1016/j.lungcan.2008.11.016. Epub 2009 Jan 7.

15.

Anti-Inflammatory Agents for Cancer Therapy.

Rayburn ER, Ezell SJ, Zhang R.

Mol Cell Pharmacol. 2009;1(1):29-43.

16.

RYBP stabilizes p53 by modulating MDM2.

Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R.

EMBO Rep. 2009 Feb;10(2):166-72. doi: 10.1038/embor.2008.231. Epub 2008 Dec 19.

17.

Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Rayburn ER, Zhang R.

Drug Discov Today. 2008 Jun;13(11-12):513-21. doi: 10.1016/j.drudis.2008.03.014. Epub 2008 May 3. Review.

18.

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.

Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, Wang H.

Prostate. 2008 Jun 1;68(8):809-19. doi: 10.1002/pros.20742.

PMID:
18324646
19.

20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.

Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R.

Br J Cancer. 2008 Feb 26;98(4):792-802. doi: 10.1038/sj.bjc.6604227. Epub 2008 Feb 5.

20.
21.

Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.

Wang H, Li M, Lin W, Wang W, Zhang Z, Rayburn ER, Lu J, Chen D, Yue X, Shen F, Jiang F, He J, Wei W, Zeng X, Zhang R.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):789-95.

22.
23.

Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.

Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R.

Oncogene. 2007 Aug 2;26(35):5029-37. Epub 2007 Feb 19.

PMID:
17310983
25.
26.
27.

In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng.

Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R.

Cancer Chemother Pharmacol. 2007 Apr;59(5):589-601. Epub 2006 Aug 22.

PMID:
16924497
28.

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R.

Mol Cancer Ther. 2006 Jun;5(6):1585-92.

29.

Antisense-based cancer therapeutics: are we there yet?

Rayburn ER, Wang H, Zhang R.

Expert Opin Emerg Drugs. 2006 May;11(2):337-52. Review.

PMID:
16634705
30.

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(6):397-407. Review.

PMID:
16336004
31.

Oncogenes as novel targets for cancer therapy (part III): transcription factors.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(5):327-38. Review.

PMID:
16196502
32.

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.

Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R.

Oncogene. 2005 Nov 3;24(48):7238-47.

PMID:
16170383
33.

Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(4):247-57. Review.

PMID:
16078861
34.

Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H.

Am J Pharmacogenomics. 2005;5(3):173-90. Review.

PMID:
15952871

Supplemental Content

Loading ...
Support Center